We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging CareDx (CDNA) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has CareDx (CDNA - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
CareDx is one of 918 companies in the Medical group. The Medical group currently sits at #10 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. CareDx is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for CDNA's full-year earnings has moved 113.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, CDNA has returned 170.1% so far this year. Meanwhile, the Medical sector has returned an average of 4.3% on a year-to-date basis. This means that CareDx is performing better than its sector in terms of year-to-date returns.
Concentra Group (CON - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 75.2%.
Over the past three months, Concentra Group's consensus EPS estimate for the current year has increased 4.7%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, CareDx belongs to the Medical Services industry, a group that includes 72 individual stocks and currently sits at #87 in the Zacks Industry Rank. On average, stocks in this group have gained 2.9% this year, meaning that CDNA is performing better in terms of year-to-date returns. Concentra Group is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to CareDx and Concentra Group as they could maintain their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging CareDx (CDNA) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has CareDx (CDNA - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
CareDx is one of 918 companies in the Medical group. The Medical group currently sits at #10 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. CareDx is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for CDNA's full-year earnings has moved 113.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, CDNA has returned 170.1% so far this year. Meanwhile, the Medical sector has returned an average of 4.3% on a year-to-date basis. This means that CareDx is performing better than its sector in terms of year-to-date returns.
Concentra Group (CON - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 75.2%.
Over the past three months, Concentra Group's consensus EPS estimate for the current year has increased 4.7%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, CareDx belongs to the Medical Services industry, a group that includes 72 individual stocks and currently sits at #87 in the Zacks Industry Rank. On average, stocks in this group have gained 2.9% this year, meaning that CDNA is performing better in terms of year-to-date returns. Concentra Group is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to CareDx and Concentra Group as they could maintain their solid performance.